Cargando…
Intravenous leiomyomatosis: Case series and review of the literature
INTRODUCTION: Intravenous leiomyomatosis (ILV) is a rare pathology, part of leiomyoma beyond the uterus (LBU), characterized by benign smooth muscle cell tumor outside of the uterus and mainly affecting premenopausal woman with a medical history of leiomyoma or gynecologic surgical treatment. The tr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350006/ https://www.ncbi.nlm.nih.gov/pubmed/34343794 http://dx.doi.org/10.1016/j.ijscr.2021.106257 |
_version_ | 1783735657796993024 |
---|---|
author | Mathey, M.P. Duc, C. Huber, D. |
author_facet | Mathey, M.P. Duc, C. Huber, D. |
author_sort | Mathey, M.P. |
collection | PubMed |
description | INTRODUCTION: Intravenous leiomyomatosis (ILV) is a rare pathology, part of leiomyoma beyond the uterus (LBU), characterized by benign smooth muscle cell tumor outside of the uterus and mainly affecting premenopausal woman with a medical history of leiomyoma or gynecologic surgical treatment. The treatment depends on the localization of the tumor, age of the patient, initial size, symptoms and the suitability for surgery but should always aims in toto surgical resection. CASE PRESENTATION: Retrospective case series and review of literature. CLINICAL DISCUSSION: Symptoms presented by the patient were aspecific and only localized in the pelvic area. All cases were fortuitous histopathological diagnosis. No relapse was. Two out of 5 patients have pulmonary nodules, only one was biopsied and diagnosed with PBML (pulmonary benign metastasizing leiomyoma). CONCLUSION: IVL and BML are rare disease that can co-exist. Because of tumoral hormonal receptors, hormonotherapy could be an optional treatment but to date no clear efficacy is demonstrated. In case of high recurrence risk such as voluminous initial mass, impairment of broad ligament, failure of total surgical resection, adjuvant hormonotherapy could be useful. Recurrence rate is about 16.6-30% and can occur even dozen years later and even after radical surgery, justifying a regular follow up. |
format | Online Article Text |
id | pubmed-8350006 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-83500062021-08-15 Intravenous leiomyomatosis: Case series and review of the literature Mathey, M.P. Duc, C. Huber, D. Int J Surg Case Rep Case Report INTRODUCTION: Intravenous leiomyomatosis (ILV) is a rare pathology, part of leiomyoma beyond the uterus (LBU), characterized by benign smooth muscle cell tumor outside of the uterus and mainly affecting premenopausal woman with a medical history of leiomyoma or gynecologic surgical treatment. The treatment depends on the localization of the tumor, age of the patient, initial size, symptoms and the suitability for surgery but should always aims in toto surgical resection. CASE PRESENTATION: Retrospective case series and review of literature. CLINICAL DISCUSSION: Symptoms presented by the patient were aspecific and only localized in the pelvic area. All cases were fortuitous histopathological diagnosis. No relapse was. Two out of 5 patients have pulmonary nodules, only one was biopsied and diagnosed with PBML (pulmonary benign metastasizing leiomyoma). CONCLUSION: IVL and BML are rare disease that can co-exist. Because of tumoral hormonal receptors, hormonotherapy could be an optional treatment but to date no clear efficacy is demonstrated. In case of high recurrence risk such as voluminous initial mass, impairment of broad ligament, failure of total surgical resection, adjuvant hormonotherapy could be useful. Recurrence rate is about 16.6-30% and can occur even dozen years later and even after radical surgery, justifying a regular follow up. Elsevier 2021-07-31 /pmc/articles/PMC8350006/ /pubmed/34343794 http://dx.doi.org/10.1016/j.ijscr.2021.106257 Text en © 2021 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Mathey, M.P. Duc, C. Huber, D. Intravenous leiomyomatosis: Case series and review of the literature |
title | Intravenous leiomyomatosis: Case series and review of the literature |
title_full | Intravenous leiomyomatosis: Case series and review of the literature |
title_fullStr | Intravenous leiomyomatosis: Case series and review of the literature |
title_full_unstemmed | Intravenous leiomyomatosis: Case series and review of the literature |
title_short | Intravenous leiomyomatosis: Case series and review of the literature |
title_sort | intravenous leiomyomatosis: case series and review of the literature |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350006/ https://www.ncbi.nlm.nih.gov/pubmed/34343794 http://dx.doi.org/10.1016/j.ijscr.2021.106257 |
work_keys_str_mv | AT matheymp intravenousleiomyomatosiscaseseriesandreviewoftheliterature AT ducc intravenousleiomyomatosiscaseseriesandreviewoftheliterature AT huberd intravenousleiomyomatosiscaseseriesandreviewoftheliterature |